Weight & Metabolic

The Medicare GLP-1 Bridge Is Live: Who Qualifies, and How to Actually Use It

By the US Health Digest editorial team · July 26, 2026

As of July 1, 2026, eligible Medicare Part D enrollees can get certain GLP-1 weight-loss medications for a flat $50 monthly copayment under the Medicare GLP-1 Bridge — a temporary demonstration, not a permanent benefit, scheduled to end December 31, 2027. There is no application to mail in: per the government's own instructions, access runs through your prescriber, a prior authorization, and your pharmacy. This article walks through eligibility and mechanics as medicare.gov and CMS describe them, and flags what the sources do not yet establish. It is not medical or insurance advice.

What the Bridge is — and what it isn't

Medicare Part D has long been barred by statute from covering drugs used for weight loss alone, as KFF explains. The Bridge does not repeal that bar. It is a time-limited demonstration that CMS says runs from July 1, 2026 through December 31, 2027 — a window KFF notes was already extended once, from an originally announced end date of December 31, 2026. It also operates separately from Part D: per KFF, Part D plans do not have to opt in and bear no financial risk, and per CMS, the Part D deductible does not apply and no part of the $50 copay counts toward your out-of-pocket (TrOOP) costs. KFF puts the same point concretely: the copay will not count toward the $2,100 Part D out-of-pocket maximum in 2026.

Three drugs are covered, and the formulations matter. Per medicare.gov: Foundayo (orforglipron) tablets, Wegovy (semaglutide) as injection or tablet, and Zepbound (tirzepatide) in the KwikPen only — the program does not cover Zepbound single-dose vials or pens. Other GLP-1s are not part of the Bridge. (For how the new tablets compare to injections, see our guide to oral GLP-1 pills.)

Behind the flat copay, KFF reports the manufacturers agreed to supply these Medicare-model drugs at a net price of $245 per month; pharmacies collect the $50 and bill the remainder to a central processor.

Who qualifies: the eligibility walkthrough

Per medicare.gov, you must be 18 or older and enrolled in Medicare drug coverage (Part D), and your prescriber must attest — via prior authorization — that you fall into one of three BMI-based tiers at the time you started GLP-1 therapy:

• BMI 35 or higher — no additional condition required;
• BMI 30 to 34.9 plus at least one of: diastolic heart failure, uncontrolled hypertension, or chronic kidney disease (stage 3a or higher);
• BMI 27 to 29.9 plus at least one of: prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.

Just as important is who is excluded. Per the same medicare.gov page, you are not eligible if you already receive a GLP-1 through your existing Part D coverage, or if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. If one of those diagnoses applies to you, the coverage conversation belongs with your prescriber and your Part D plan rather than the Bridge — Part D's statutory bar, per KFF, is specific to weight loss alone. medicare.gov hosts an interactive questionnaire at Medicare.gov/glp1bridge to check your own situation, and CMS lists 1-800-MEDICARE (1-800-633-4227; TTY 1-877-486-2048) for questions.

One thing the public pages do not spell out: precise definitions for terms like "uncontrolled hypertension," or whether the comorbidity lists above are exhaustive on the prior authorization form itself. Your prescriber's office, working from the actual form, is the authority on whether your chart supports the attestation.

How to actually get it: the verified steps

There is no beneficiary enrollment form described anywhere in the government materials we reviewed — medicare.gov describes access in three steps, and CMS's pages for providers and pharmacies fill in the machinery:

1. Your prescriber sends a prescription to your pharmacy for one of the three covered drugs. Per CMS, the prescriber does not need to be enrolled in Medicare (though they cannot be on Medicare's Preclusion List), and can direct the pharmacist to send the claim to the Bridge.
2. The pharmacy triggers the prior authorization. Per CMS, the pharmacy transmits the prior authorization request to the prescriber (typically within 24–72 hours), the prescriber submits the form electronically or by fax, and the approval or denial is mailed to you and sent to the prescriber within 72 hours of submission. The attestation states that the drug is prescribed "to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the applicable FDA approved label."
3. You fill at the pharmacy and pay $50. Any pharmacy can participate — per CMS, "pharmacies do not need to opt-in," they collect the $50 copay, and a central processor reimburses them. Once your first fill is approved, refills do not require a new prior authorization unless you switch to a different covered drug.

Fills are capped at a single monthly supply of 28 or 30 days; per CMS, 60- and 90-day fills are not available.

What it costs

The hard question: what happens on January 1, 2028

The Bridge's end date is not fine print — it is the central planning fact for anyone starting now. These are long-term medications, and the best evidence on stopping them is sobering: in the SURMOUNT-4 trial, participants switched from tirzepatide to placebo regained a substantial portion of the weight they had lost, while those who continued kept losing. Whether the Bridge is extended again, replaced, or simply lapses after December 31, 2027 is not established by any current government source — the program's own materials commit only to the current window. A woman starting in mid-2026 should ask her prescriber, before the first fill, what the plan is if coverage ends: taper, transition, self-pay, or another route. For readers in midlife and beyond, the maintenance question interacts with muscle and bone considerations we cover in GLP-1s for women over 40.

Questions to ask your plan and prescriber

• "At the time I would start (or started) a GLP-1, which of the three BMI tiers does my chart support — and is the supporting diagnosis documented?"
• "Do any of the exclusions apply to me — an existing Part D GLP-1 fill, type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease? If so, would my Part D plan cover a GLP-1 for that diagnosis instead?"
• "Which covered form would you prescribe — Foundayo tablet, Wegovy injection or tablet, or Zepbound KwikPen — given that other formulations aren't covered?"
• "Will your office handle the prior authorization when the pharmacy sends it, and how quickly?"
• "What is our plan for December 31, 2027 if the program is not extended?"
• To your Part D plan: "Does anything about my current drug coverage change because I'm using the Bridge?" (The program runs outside Part D, but confirm your own plan's understanding.)

If you're denied — and how this fits the bigger coverage picture

A Bridge prior-authorization denial arrives by mail, per CMS — and CMS is blunt about what comes next: "There is no appeals process under Medicare GLP-1 Bridge." The one recourse the same page describes is resubmission — a prescriber may resubmit the prior authorization form if the original contained incorrect information or if there is updated or additional information to include. So a denial letter is a prompt to call your prescriber's office, not a Part D appeals packet; for anything unclear, ask the program through 1-800-MEDICARE and read the denial notice for its own instructions. If your denial is instead a conventional one — a Part D or commercial plan refusing a GLP-1 — the deadlines and levels are well defined, and we walk through them in our guide to appealing a GLP-1 coverage denial. And if you are sorting out where the Bridge sits among Medicare, Medicaid — where KFF counts just 13 states covering weight-loss drugs as of January 2026, down from 16 — and employer plans, start with our full GLP-1 insurance coverage guide.

Program rules for a new demonstration can change quickly. Before acting on anything above, confirm the current terms at Medicare.gov/glp1bridge — and make the treatment decision itself with a clinician who knows your history.